174 related articles for article (PubMed ID: 10650803)
21. Isoenzymes of alkaline and acid phosphatases as bones metastasis marker in breast cancer patients.
Desoize B; Veiler V; Pourny C; Comoe L; Jardillier JC
Anticancer Res; 1989; 9(4):1105-9. PubMed ID: 2817792
[TBL] [Abstract][Full Text] [Related]
22. [Development for the determination of band 5b tartrate-resistant acid phosphatase activity in serum].
Uchida K; Nakanishi M; Yoh K
Rinsho Byori; 2001 Jan; 49(1):51-5. PubMed ID: 11215484
[TBL] [Abstract][Full Text] [Related]
23. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
[TBL] [Abstract][Full Text] [Related]
24. Plasma acid and alkaline phosphatase in patients with breast cancer.
Nguyen M; Bonneterre J; Hecquet B; Desoize B; Demaille A
Anticancer Res; 1991; 11(2):831-3. PubMed ID: 2064338
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the activity of tartrate-resistant acid phosphatase isoform 5b in normal Chinese children--a novel marker for bone growth.
Chen CJ; Chao TY; Janckila AJ; Cheng SN; Ku CH; Chu DM
J Pediatr Endocrinol Metab; 2005 Jan; 18(1):55-62. PubMed ID: 15679069
[TBL] [Abstract][Full Text] [Related]
26. Potential role of tartrate-resistant acid phosphatase 5b (TRACP 5b) as a surrogate marker of late loosening in patients with total hip arthroplasty: a cohort study.
Savarino L; Avnet S; Greco M; Giunti A; Baldini N
J Orthop Res; 2010 Jul; 28(7):887-92. PubMed ID: 20063383
[TBL] [Abstract][Full Text] [Related]
27. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer.
Lyubimova NV; Pashkov MV; Tyulyandin SA; Gol'dberg VE; Kushlinskii NE
Bull Exp Biol Med; 2004 Jul; 138(1):77-9. PubMed ID: 15514730
[TBL] [Abstract][Full Text] [Related]
28. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.
Halleen JM; Tiitinen SL; Ylipahkala H; Fagerlund KM; Väänänen HK
Clin Lab; 2006; 52(9-10):499-509. PubMed ID: 17078477
[TBL] [Abstract][Full Text] [Related]
29. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK
Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
[TBL] [Abstract][Full Text] [Related]
30. Development of immunoassays for serum tartrate-resistant acid phosphatase isoform 5a.
Chao TY; Lee SH; Chen MM; Neustadt DH; Chaudhry UA; Yam LT; Janckila AJ
Clin Chim Acta; 2005 Sep; 359(1-2):132-40. PubMed ID: 15993395
[TBL] [Abstract][Full Text] [Related]
31. Tartrate-resistant acid phosphatase 5b is a potential biomarker for rheumatoid arthritis: a pilot study in Han Chinese.
Cheng T; Wang M; Chen Z; Eisenberg RA; Zhang Y; Zou Y; Deng Y; Wang M; Zhou L
Chin Med J (Engl); 2014; 127(16):2894-9. PubMed ID: 25131223
[TBL] [Abstract][Full Text] [Related]
32. Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis.
Wu YY; Janckila AJ; Ku CH; Yu CP; Yu JC; Lee SH; Liu HY; Yam LT; Chao TY
BMC Cancer; 2010 Apr; 10():158. PubMed ID: 20416078
[TBL] [Abstract][Full Text] [Related]
33. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
[TBL] [Abstract][Full Text] [Related]
34. Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer.
Wang R; Zhang S; Jiang Z; Tian J; Wang T; Song S
Clin Exp Pharmacol Physiol; 2017 Jan; 44(1):88-93. PubMed ID: 27716993
[TBL] [Abstract][Full Text] [Related]
35. Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment.
Fagerlund KM; Janckila AJ; Ylipahkala H; Tiitinen SL; Nenonen A; Cheng S; Uusi-Rasi K; Yam LT; Väänänen HK; Halleen JM
Clin Lab; 2008; 54(9-10):347-54. PubMed ID: 19097492
[TBL] [Abstract][Full Text] [Related]
36. Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D; Karlikova M; Svobodova J
Anticancer Res; 2016 Apr; 36(4):1973-8. PubMed ID: 27069189
[TBL] [Abstract][Full Text] [Related]
37. [Novel markers in osteo-oncology: the tartrate resistant acid phosphatase in myeloma bone disease].
Strippoli S; Stucci S; Dammacco F; Silvestris F
Recenti Prog Med; 2011 Feb; 102(2):88-95. PubMed ID: 21513124
[TBL] [Abstract][Full Text] [Related]
38. Specificity and clinical performance of two commercial TRACP 5b immunoassays.
Ylipahkala H; Fagerlund KM; Janckila AJ; Houston B; Laurie D; Halleen JM
Clin Lab; 2009; 55(5-6):223-8. PubMed ID: 19728556
[TBL] [Abstract][Full Text] [Related]
39. Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum.
Nakanishi M; Yoh K; Miura T; Ohasi T; Rai SK; Uchida K
Clin Chem; 2000 Apr; 46(4):469-73. PubMed ID: 10759470
[TBL] [Abstract][Full Text] [Related]
40. Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease.
Janckila AJ; Lederer ED; Price BA; Yam LT
Clin Nephrol; 2009 Apr; 71(4):387-96. PubMed ID: 19356371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
